Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.

Ong KL, Rye KA, O'Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech AC; FIELD study investigators.

J Clin Endocrinol Metab. 2012 Dec;97(12):4701-8. doi: 10.1210/jc.2012-2267. Epub 2012 Nov 8.

PMID:
23144467
2.

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA.

Diabetologia. 2015 Mar;58(3):464-73. doi: 10.1007/s00125-014-3458-7. Epub 2014 Nov 26.

PMID:
25425220
3.

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Ong KL, Januszewski AS, O'Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA, Keech AC; FIELD study investigators.

Diabetologia. 2015 Sep;58(9):2035-44. doi: 10.1007/s00125-015-3652-2. Epub 2015 Jun 9.

PMID:
26055067
4.

Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.

Wu H, Wei L, Bao Y, Lu J, Huang P, Liu Y, Jia W, Xiang K.

Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E628-34. doi: 10.1152/ajpendo.90526.2008. Epub 2008 Dec 16.

5.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
6.

Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.

Haluzík MM, Anderlová K, Dolezalová R, Adamíková A, Haluzíková D, Housová J, Svacina S, Haluzík M.

Physiol Res. 2009;58(1):93-9. Epub 2008 Jan 17.

7.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
8.

Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.

Anderlová K, Dolezalová R, Housová J, Bosanská L, Haluzíková D, Kremen J, Skrha J, Haluzík M.

Physiol Res. 2007;56(5):579-86. Epub 2006 Dec 19.

9.

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators.

Cardiovasc Diabetol. 2005 Aug 22;4:13.

10.

Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.

Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y, Tan Y, Feng W, Fu Y, Mellen N, Cheng R, Ma J, Zhang C, Li Z, Cai L.

Clin Sci (Lond). 2016 Apr;130(8):625-41. doi: 10.1042/CS20150623. Epub 2016 Jan 21.

PMID:
26795437
11.

The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.

Black RN, Ennis CN, Young IS, Hunter SJ, Atkinson AB, Bell PM.

J Diabetes Complications. 2014 May-Jun;28(3):323-7. doi: 10.1016/j.jdiacomp.2014.01.001. Epub 2014 Jan 8.

PMID:
24560135
12.

Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M.

Clin Endocrinol (Oxf). 2009 Sep;71(3):369-75. doi: 10.1111/j.1365-2265.2008.03502.x. Epub 2008 Dec 11.

PMID:
19702724
13.

Serum retinol binding protein 4 level is related with renal functions in Type 2 diabetes.

Akbay E, Muslu N, Nayir E, Ozhan O, Kiykim A.

J Endocrinol Invest. 2010 Nov;33(10):725-9. doi: 10.3275/7024. Epub 2010 Apr 30.

PMID:
20436266
14.

Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.

Playford DA, Watts GF, Croft KD, Burke V.

Atherosclerosis. 2003 May;168(1):169-79.

PMID:
12732401
15.

Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.

Harmer JA, Keech AC, Veillard AS, Skilton MR, Marwick TH, Watts GF, Meredith IT, Celermajer DS; FIELD Vascular Study Investigators.

Atherosclerosis. 2015 Sep;242(1):295-302. doi: 10.1016/j.atherosclerosis.2015.07.038. Epub 2015 Jul 23.

PMID:
26233916
16.

Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators.

Diabetologia. 2014 Nov;57(11):2296-303. doi: 10.1007/s00125-014-3344-3. Epub 2014 Aug 23. Erratum in: Diabetologia. 2015 Sep;58(9):2200.

PMID:
25149070
17.

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators.

Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4.

PMID:
21052978
18.

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.

Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR.

Diabetes Care. 2010 Feb;33(2):215-20. doi: 10.2337/dc09-0621. Epub 2009 Oct 21. Erratum in: Diabetes Care. 2010 May;33(5):1151.

19.

The role of fenofibrate in clinical practice.

Zambon A, Cusi K.

Diab Vasc Dis Res. 2007 Sep;4 Suppl 3:S15-20.

PMID:
17935056
20.

Serum FGF21 and RBP4 levels in patients with chronic hepatitis C.

Kukla M, Berdowska A, Stygar D, Gabriel A, Mazur W, Łogiewa-Bazger B, Sobala-Szczygieł B, Bułdak RJ, Rokitka M, Zajęcki W, Kępa L, Sawczyn T, Zwirska-Korczala K.

Scand J Gastroenterol. 2012 Sep;47(8-9):1037-47. doi: 10.3109/00365521.2012.694901. Epub 2012 Jun 7.

PMID:
22670657

Supplemental Content

Support Center